overvåges tæt for tegn og symptomer på aktiv HBV- infektion gennem behandlingen og i adskillige måneder efter afslutningen af behandlingen.
Carriers of HBV who require treatment with Trudexa should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.